Connect with us

Business

North East business rides out tough economic conditions as insolvency activity falls

Published

on

Business Live

The 2025 figures from R3for the region show a 9.3% decrease in insolvency-related activity,

The latest R3 annual report has been published

The latest R3 annual report has been published(Image: Getty Images)

North East businesses have weathered a challenging year with the region chalking up a drop in insolvency-related activity, a new report suggests. The latest annual report from R3 – the trade body for restructuring, turnaround and insolvency professionals – also shows an increase in the number of new start-ups.

Supported by data from CreditSafe, R3’s reports examine insolvency and start-up activity, highlights sectors under financial stress, and explores key business pressures. The 2025 figures for the region show a 9.3% decrease in insolvency-related activity, which includes administrations and creditors’ meetings as well as voluntary and compulsory liquidations from 863 cases in 2024 to 783 last year.

However, levels of insolvency activity still remain much higher than five years ago. There was a 3.3% increase over the same period in the number of start-up businesses which rose from 16,897 to 17,455.

In a year-on-year regional comparison the North East was one of the best performing areas, with its annual decline in insolvency related activities topped only by Yorkshire and Humber with a 9.9% decrease and Greater London’s 11% drop.

Advertisement

The R3 Annual Business Health Report also explores sector trends across the UK, with the national picture highlighting a fragile operating environment for many businesses.

Construction continued to account for the highest number of insolvency activities in the UK in 2025 (4,584 cases), despite a modest reduction of 6% on the previous year. The sector was impacted by rising material costs as well as delayed payments, skills shortages and weak investor confidence.

Aerial view of Union Electric Steel plant at Gateshead

Aerial view of Union Electric Steel plant at Gateshead(Image: Avison Young)

Within the North East, Cramlington based construction specialist Merit went into administration towards the end of the year, with the loss of around 340 jobs, while Union Electric Steel also closed its North East operation in Gateshead, with the loss of 156 jobs. Directors at Merit have since bought assets of the business from administrators to start a new company.

Elsewhere in the UK wholesale and retail (4,124 cases) and accommodation and food services (3,831 cases) also saw rising insolvency activity, reflecting pressure on margins as hard-pressed opted to save rather than spend, in discretionary spending and businesses struggled to absorb or pass on higher costs.

Advertisement

Manufacturing insolvencies also remained historically high with 2,188 cases, as companies battled energy costs, supply chain disruption and subdued export demand.

Kelly Jordan, North East Chair of R3, and partner at Muckle LLP, said: “The R3 report shows that businesses, both regionally and nationally, struggled to regain their footing in 2025 after several years of economic challenges.

“While inflation has now eased, the cumulative impact of higher costs, tighter credit conditions and weak demand continues to place significant pressure on local companies, particularly smaller and mid-sized firms with limited financial headroom.

“As we move into 2026, while cashflow and profit margins remain under pressure, seeking professional advice at an early stage from an R3 member can make a critical difference, giving viable businesses the best chance of survival and recovery.”

Advertisement
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Gold, Silver Prices Surge to Reignite Rally. Why They’re Rebounding After Selloff.

Published

on

Gold, Silver Prices Surge to Reignite Rally. Why They’re Rebounding After Selloff.

Gold, Silver Prices Surge to Reignite Rally. Why They’re Rebounding After Selloff.

Continue Reading

Business

No immediate steps planned to regulate equity derivatives: Tuhin Kanta Pandey

Published

on

No immediate steps planned to regulate equity derivatives: Tuhin Kanta Pandey
The Securities and Exchange Board of India (Sebi) is not planning any immediate measures to regulate equity derivatives, chairperson Tuhin Kanta Pandey said on Wednesday.

“At this moment, we are not contemplating any measures, and whatever framework that we have put in place, that will continue,” Pandey said. “When we as a regulator look at derivative markets, we do so in a very methodical manner based on data.”

The government raised transaction taxes on equity derivatives in the Union Budget to curb speculative trading. India’s futures and options volumes are more than 500 times the country’s GDP, underscoring the need for arate adjustment to rein in excessive activity, it said.

Separately, on the US-India trade deal, he said it would help get more investments into the country.

Advertisement

“Fundamentally, when you have an overhang of a regulatory action which is removed, and trade frictions removed, capital formation is always accelerated,” Pandey said. He added that the removal of the uncertainties can spur investment decisions and get a greater predictability on capital. “So overall in the situation I could say that with the deals that have been done on the trade side, a lot of uncertainties have been removed,” he said.


Algo Trades may Soon Not Face OTR Penalties
The Securities and Exchange Board of India (Sebi) on Wednesday proposed changes to its order-to-trade ratio (OTR) framework for equity options, to exempt algorithmic orders placed by market makers from OTR penalties.
Under the revised framework, for equity option contracts, orders placed within a range of 40% above or below the last traded price (premium) “or ± ₹20, whichever is higher, shall be exempted from the framework for imposing penalty for high OTR,” the regulator said in a circular.At present, stock exchanges place economic disincentive for high order-to-trade ratio of algorithmic orders placed by stockbrokers. Further, algorithmic orders placed by designated market makers for market making activity would not be considered towards computation of OTR, Sebi said. “Orders placed within the range of ±0.75% of the LTP shall be exempted from the framework for imposing penalty for high OTR,” it said

No Fresh Curbs on Equity Derivatives
Pandey was speaking at the launch of a corporate-bond outreach event, where he noted that measures are being considered to deepen the bond market. Sebi will engage with market participants on implementing the Budget proposals related to corporate bonds, he said.

The recent Budget has proposed a series of reforms aimed at improving liquidity in the secondary market.

“A market-making framework will support continuous twoway quotes, reduce bid-ask spreads, and improve price discovery, thereby making corporate bonds a more reliable asset class for investors,” Pandey said. “Derivatives on corporate-bond indices and total-return swaps will help investors in efficient risk management. As secondary-market liquidity improves and investor base widens, the corporate-bond markets will become a more reliable and cheaper funding route for issuers.”

Advertisement

In FY25, issuers raised about ₹10 lakh crore through debt issuances. Outstanding corporate bonds have grown at roughly 12% CAGR, rising from ₹17.5 lakh crore in FY15 to ₹58 lakh crore by end-December 2025, according to Sebi data.

Pandey noted that the market remains heavily skewed towards highly rated issuers, who account for 90% of all bond issuances. Nearly 60% of funds are raised by financial institutions, limiting sectoral diversity.

“This concentration limits the choice available to investors and restricts fair price discovery across different sectors of the economy. The secondary market remains shallow because institutional investors follow a ‘buy-andhold’ approach rather than active trading,” he said.

This is further compounded by the dominance of private placements, which can reduce transparency and make it harder for smaller issuers to access the market, he added.

Advertisement

More than 5,600 companies are listed in the equity market, but only about 770 entities have raised funds through the debt market. Of these, 272 have tapped the market multiple times, while many have issued debt only once or twice, Sebi data showed.
He also said a Sebi survey showed that more Indians know about crypto currencies than about bonds.

Continue Reading

Business

Motilal Oswal urges balanced portfolio mix as India-US trade deal lifts sentiment

Published

on

Motilal Oswal urges balanced portfolio mix as India-US trade deal lifts sentiment
Motilal Oswal Private Wealth is advising investors to adopt a balanced allocation strategy — anchoring portfolios with large-cap or hybrid funds, and complementing them with staggered exposure to midand small-caps — with sentiment improving following the finalisation of the India-US trade deal.

“Investors could allocate 50% to large caps and hybrids, 40% to mid and small caps, and 10% to global markets,” says Ashish Shanker, MD & CEO, Motilal Oswal Private Wealth. He recommends making lumpsum allocations to large caps and hybrids immediately, while staggering investments into mid and small caps over the next couple of months. Within global markets, he favours emerging-market exposure.

Following the sharp run-up in silver prices, the wealth manager suggests partial profit-booking for investors with heavy exposure, while maintaining a neutral stance on gold for portfolio stability. Those under-allocated to gold can consider gradual accumulation on dips for ‘moderate’ medium-term returns.

Continue Reading

Business

More drops for technology stocks weigh on Wall Street

Published

on

More drops for technology stocks weigh on Wall Street

More drops for technology stocks weighed on Wall Street Wednesday.

Continue Reading

Business

Baidu announces $5 billion share buyback program and first dividend

Published

on


Baidu announces $5 billion share buyback program and first dividend

Continue Reading

Business

Asian stocks fall after tech selloff, gold gains

Published

on

Asian stocks fall after tech selloff, gold gains
Asian stocks dropped for a second day after Wall Street investors moved out of technology firms and rotated into a broader range of companies amid concerns about high valuations and spending.

The MSCI Asia Pacific Index dropped 0.3% at the open. The Kospi Index in South Korea — a poster child for artificial intelligence investments and the best-performing index worldwide this year — led the losses, dropping 1.6%.

The Asian moves came after the Nasdaq 100 saw its worst two-day rout since October, breaching its 100-day moving average, a level seen by some technical analysts as a harbinger for more losses. Futures contracts for US gauges, however, rose 0.3% in early Asian trading, indicating selling pressure may be easing.

Elsewhere, gold and silver advanced, continuing their rebound from a historic plunge, while Bitcoin trimmed some of its losses. The yen was a touch weaker at 156.93 to a dollar on Thursday, extending its losses with elections in Japan set for the weekend. The Bloomberg Dollar Spot Index held its gains from the prior session.

Advertisement

The tech-heavy selloff reflected further concerns among investors regarding tech valuations, high levels of spending and the potential for AI to cannibalize established software business models. In tech-related earnings, Alphabet Inc. shares fell in extended trading after outlining an ambitious capital spending plan, while Arm Holdings Plc slipped post-market on a disappointing sales forecast, and Qualcomm Inc. gave a lackluster revenue outlook.


“There might be a glass half full and a glass half empty perspective on the moves here,” said Kyle Rodda at Capital.com. “On the one hand, tech stocks are potentially too richly valued. On the other hand, the strength in the market is broadening out in a sign of improving economic fundamentals.”

814x-1 (6)Bloomberg

In other corners of the market, Bitcoin hovered near $73,000, with prediction traders betting the world’s most popular cryptocurrency will drop below $65,000. Treasuries were mixed on Wednesday, with the short-end of the curve rallying. The US two-year yield fell two basis points while the 10-year ended one basis point higher.
The pound and euro were steady ahead of interest rate decisions due later Thursday. The European Central Bank and Bank of England are expected to leave rates unchanged.
Meanwhile, clear signs of momentum behind the tech sell-off emerged. The iShares MSCI USA Momentum Factor ETF plunged 3.7%, while a Goldman Sachs Group Inc. basket that goes long high-beta momentum names and short the opposite tumbled 9.8%.

Rotation out of tech was the main theme during the US session and software firms saw another wave of selling, but moves were bigger in chipmakers. A Bloomberg gauge of the so-called Magnificent Seven companies fell 1.8%.

What Bloomberg strategists say…
What looks like a brutal equity rotation away from concentration is actually proving to be a bright spot for the broader market. US equities are experiencing a rotation that in the moment seems painful, but was ultimately inevitable.

— Brendan Fagan, Macro Strategist.

Advertisement

Traders are also paying attention to the moves in the precious metals. Gold and silver rose for a third consecutive day after retreating from a record on Friday.

Precious metals soared last month in a rally underpinned by speculative momentum, geopolitical upheaval and concerns about the Federal Reserve’s independence. The surge came to a sudden halt at the end of last week, with silver seeing its biggest ever daily drop on Friday and gold plunging the most since 2013.

Gold traded just above $5,000 an ounce and silver was about $89.

In the US, service providers saw the strongest back-to-back growth since 2024 as business activity picked up even as employment barely expanded. While companies added fewer jobs than expected, recent data has pointed to limited layoffs.

Advertisement

Elsewhere, US President Donald Trump and President Xi Jinping of China discussed trade and geopolitical flashpoints, including Taiwan, during a Wednesday call ahead of a planned face-to-face meeting later this year.

In commodities, oil fell for the first time in three days after Iran confirmed it would hold negotiations with the US, easing the immediate risk of military strikes against the OPEC producer.

Continue Reading

Business

AMD CEO Lisa Su Confirms Valve’s Steam Machine On Track for Early 2026 Shipping

Published

on

Samsung Galaxy S26 Ultra Set for February 25 Unveiling at

Advanced Micro Devices Inc. (AMD) CEO Dr. Lisa Su said Tuesday that Valve Corp. remains on schedule to begin shipping its long-awaited AMD-powered Steam Machine in the early months of 2026, providing the strongest third-party confirmation yet of the device’s imminent arrival.

Speaking during AMD’s fourth-quarter 2025 earnings call on Feb. 3, Su highlighted progress on the company’s semi-custom system-on-chip (SoC) business, which includes custom silicon for gaming consoles and handhelds. She specifically addressed Valve’s project amid broader commentary on AMD’s partnerships with major platform holders.

“From a product standpoint, Valve is on track to begin shipping its AMD-powered Steam Machine early this year,” Su stated in prepared remarks. She paired the update with news that development of Microsoft’s next-generation Xbox SoC is “progressing well to support a launch in 2027.”

The comments come as Valve, the Bellevue, Washington-based gaming giant behind the Steam platform and Steam Deck handheld, prepares to expand its hardware lineup. Valve first teased the revival of the Steam Machine concept in late 2025, describing it as a compact, living-room-focused gaming PC running SteamOS and optimized for couch play. Unlike the original Steam Machines launched in 2015 — which struggled with limited game compatibility and fragmented hardware partners — the new iteration builds directly on the success of the Steam Deck, leveraging SteamOS improvements and a broader library of verified titles.

Advertisement

Details on the device’s specifications remain limited, but industry reports indicate it features a semi-custom AMD APU combining Zen 4 CPU architecture with RDNA 3 graphics. Valve has described the Steam Machine as significantly more powerful than the Steam Deck — potentially up to six times in certain workloads — positioning it to deliver 4K gaming at 60 frames per second in many titles when connected to a television or monitor. The system is expected to include modern connectivity options, expandable storage, and compatibility with a wide range of PC peripherals.

Su’s affirmation carries weight because AMD serves as the primary silicon supplier for the device. The company’s semi-custom division has powered every major console generation in recent years, including current Xbox and PlayStation hardware, as well as the Steam Deck. Investors and analysts closely monitor these updates for clues on production timelines and revenue implications.

Despite the positive note, key consumer details — including exact pricing, configuration options, and a firm ship date — have not been disclosed by Valve. Speculation from analysts and leaks suggests a starting price in the $700–$800 range to compete with mid-tier gaming PCs and current-generation consoles like the PlayStation 5 and Xbox Series X/S. Valve previously indicated the Steam hardware family, which may include additional devices like an updated Steam Controller or Steam Frame accessory, would ship in early 2026.

The original Steam Machines, released over a decade ago, faced challenges in a market dominated by traditional consoles and high-end PCs. Many reviewers criticized the ecosystem’s reliance on Proton compatibility layers for Windows games and the lack of exclusive titles. Valve quietly discontinued the initiative but retained lessons that informed the Steam Deck’s 2022 launch, which has sold millions of units and established SteamOS as a viable Linux-based gaming platform.

Advertisement

Industry observers view the new Steam Machine as Valve’s bid to capture living-room gaming share amid rising interest in PC-handheld hybrids and cloud gaming alternatives. The device could appeal to PC gamers seeking a console-like experience without subscriptions, while leveraging Steam’s vast library and frequent sales. Its success may hinge on seamless integration with existing Steam accounts, controller support, and performance that justifies the premium over budget mini-PCs.

AMD’s semi-custom revenue is expected to decline significantly in 2026 as the current console cycle matures, Su noted during the call. However, new projects like the Steam Machine and future Xbox contributions could help offset that trend in subsequent years.

Valve has remained characteristically tight-lipped since the initial 2025 announcement, with no official updates following Su’s remarks. The company did not immediately respond to requests for comment.

For gamers and investors alike, Su’s comments reduce uncertainty around the Steam Machine’s timeline at a moment when handheld and mini-console markets continue to heat up. If Valve delivers on the early 2026 window, the device could arrive in time to influence holiday purchasing decisions later in the year or set the stage for broader Steam hardware ecosystem growth.

Advertisement
Continue Reading

Business

Bank of England expected to hold interest rates

Published

on

Bank of England expected to hold interest rates

Interest rates were cut to 3.75% in December and analysts expect at least one further reduction this year.

Continue Reading

Business

Eli Lilly gaining in GLP-1 market over Novo Nordisk, earnings show

Published

on

Eli Lilly gaining in GLP-1 market over Novo Nordisk, earnings show

The Eli Lilly and Novo Nordisk logos.

Mike Blake | Tom Little | Reuters

It’s a tale of two drugmakers in the red-hot obesity drug market. 

Advertisement

Both Novo Nordisk and Eli Lilly are grappling with lower prices in the U.S., but their 2026 outlooks are diverging sharply: While Novo is bracing for a sales decline, Lilly sees revenue jumping again thanks to its blockbuster medicines. 

The split in guidance — despite similar headwinds — underscores the strength of Lilly’s position in the obesity and diabetes drug market, underpinned by its more effective injections and early foray into direct-to-consumer sales, among other factors. While Novo Nordisk effectively made the drugs mainstream, Lilly has since taken a clear edge in market share — and the forecasts show it will likely only extend its advantage this year.

“The difference in sales momentum and market share trend was visible throughout 2025, but the dichotomy between the two companies’ prospects was accentuated within this 24-hour period in which Novo guided below consensus and Lilly guided above consensus expectations,”  Leerink Partners analyst David Risinger told CNBC on Wednesday. 

“That really solidified an investor’s mind that Lilly is going to be the dominant player in obesity going forward,” he added. 

Advertisement

This year, all eyes will be on how Lilly’s upcoming obesity pill, orforglipron, fares against Novo’s own oral Wegovy drug, which has had an explosive U.S. launch this year.

In an interview on CNBC’s “Squawk Box” on Wednesday, Lilly CEO David Ricks said 20 million to 25 million patients are currently taking both companies’ medicines. But he said the total addressable market of patients in the obesity space is “gigantic.” 

Eli Lilly CEO David Ricks on Q4 results: We're the market leader in both diabetes and obesity now

Diverging outlooks

On Wednesday, Lilly forecasted 2026 sales of $80 billion to $83 billion, surpassing the $77.62 billion that analysts were expecting, according to LSEG. 

The midpoint of that outlook translates to sales growing by 25% this year.

In contrast, Novo warned on Tuesday that it sees sales and profit declining by 5% to 13% this year, as prices fall in the U.S. and exclusivity expires for its blockbuster obesity and diabetes drugs in China, Brazil and Canada. 

Advertisement

Mike Doustdar, left, CEO of Novo Nordisk, and David Ricks, CEO of Eli Lilly, listen as President Donald Trump speaks in the Oval Office during an event about weight-loss drugs on Nov. 6, 2025.

Andrew Caballero-Reynolds | Afp | Getty Images

Lilly similarly pointed to a “global pricing decline in the low- to mid- teens [percentages] this year.” That comes after the landmark “most favored nation” deals both companies struck with President Donald Trump in November to slash obesity and diabetes drug costs, along with their recent efforts to further reduce direct-to-consumer prices for their treatments. 

The agreements with Trump are expected to take a bite out of both companies’ sales, but eventually increase volumes of prescriptions for their drugs. Still, Lilly is bullish about other factors that will help offset that pricing pressure. 

Advertisement

That includes continued worldwide demand for its obesity drug Zepbound and diabetes counterpart Mounjaro and the expected launch of its GLP-1 pill for obesity in the second quarter, pending U.S. approval. Lilly also pointed to government Medicare coverage of obesity treatments starting for the first time by at least July, one of the winning features of the drug pricing deals with Trump. 

Lilly’s Ricks told CNBC that coverage will open up access to 40 million new Medicare beneficiaries, “and that could be quite expansive to volume.”

Overall, Risinger called Lilly’s guidance “very encouraging” and said the “price per volume trade-off is playing out well” for the company.

He said tirzepatide, the active ingredient in Zepbound and Mounjaro, is “superior” in its effectiveness and tolerability compared to semaglutide, the ingredient in Novo’s obesity and diabetes drugs. That was proven in a head-to-head clinical trial conducted by Lilly in 2024, and prescription trends show that the company’s drugs are preferred among prescribers.  

Advertisement

“I think that’s what is driving Lilly’s market share gain” relative to Novo, Risinger said. 

Another factor that sets Lilly and Novo apart is patent exclusivity. While Novo said expiring patents in some international markets pose a challenge, Lilly’s Ricks said tirzepatide should be protected into “the back half of the 2030s” in major markets. 

Risinger noted that Lilly is still working to drive global uptake for tirzepatide, which won U.S. approval for obesity in 2023. 

All eyes on pills

A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026.

Advertisement

George Frey | Bloomberg | Getty Images

Novo Nordisk is first to market with a GLP-1 pill for obesity, and it hit 50,000 weekly prescriptions in just under three weeks of its launch. But investors are watching to see how that shifts once Lilly’s pill rolls out to patients later this year. 

In an interview with CNBC’s “Mad Money,” Novo CEO Mike Doustdar said he’s confident about the company’s ability to compete with Lilly. 

“Clearly we have the most efficacious weight-reduction pill that there is and I’m very optimistic and bullish on when they come with their pill and we have to battle this out,” Doustdar said. 

Advertisement

He’s referring to clinical trial data suggesting that Novo’s Wegovy pill promotes comparable weight loss to its injectable counterpart, which is around 15%. Meanwhile, Lilly’s pill appears to be slightly less effective than that, based on separate study data. 

Risinger said the launch of Novo’s pill has benefited from the fact that the company is leveraging the Wegovy brand name, which is recognizable by many patients, and immediately launched direct-to-consumer advertising for the product in early January. 

But he said Lilly could capitalize on its pill’s convenience advantage. 

Orforglipron is a small-molecule drug that is absorbed more easily in the body and doesn’t require dietary restrictions like Novo Nordisk’s pill, which is a peptide medication. Patients are supposed to drink no more than four ounces of water with the Wegovy pill and must wait 30 minutes before eating or drinking anything else each day. 

Advertisement

Novo contends that those requirements won’t hinder uptake, but Risinger said it could help Lilly’s pill eventually generate greater sales globally. 

Continue Reading

Business

Samsung Galaxy Buds 4 Set for February 25, 2026 Launch Alongside Galaxy S26 Series, Leaks Show

Published

on

Samsung Galaxy S26 Ultra Set for February 25 Unveiling at

Samsung Electronics is poised to unveil the Galaxy Buds 4 and Galaxy Buds 4 Pro on Feb. 25, 2026, during its Galaxy Unpacked event, according to multiple reliable leaks and industry reports circulating in early February.

The announcement, first hinted at by prominent leaker Evan Blass (@evleaks) via a shared Unpacked invite image, pairs the new true wireless earbuds with the flagship Galaxy S26 lineup, including the S26, S26 Plus and S26 Ultra. Blass’s post explicitly stated: “Galaxy S26 family + Galaxy Buds4 lineup launching 25 February.”

This timeline aligns with Samsung’s typical early-year Unpacked strategy for premium devices, shifting away from the mid-year releases seen with the Galaxy Buds 3 and Buds 3 Pro in July 2024. The Buds 4 series follows closely after the Galaxy Buds Core launched in June 2025, signaling accelerated iteration in Samsung’s audio lineup amid fierce competition from Apple AirPods and Sony WF-series models.

Leaked renders and certifications from sources like Android Headlines, Dealabs and regulatory bodies (including FCC, BIS in India, SIRIM in Malaysia and SGS) provide the clearest look yet at the upcoming earbuds. The Galaxy Buds 4 feature a refreshed stem design with flatter profiles and metallic accents, moving away from the blade-like stems of the Buds 3 series. The standard model adopts an open-ear fit without silicone tips, while the Buds 4 Pro includes in-ear tips for enhanced passive isolation.

Advertisement

A redesigned charging case returns to a more traditional squarish, clamshell form factor, reportedly with a transparent lid option in some variants. Color choices appear limited to black and white for both models at launch, though additional shades could follow.

Pricing leaks suggest stability despite the upgrades. The Galaxy Buds 4 are expected to retail at €179 (approximately $212 USD) in Europe, matching the Galaxy Buds 3’s launch price. The premium Galaxy Buds 4 Pro are slated for €249 (around $294 USD), holding steady from the Buds 3 Pro’s €249 positioning. U.S. estimates point to $179.99 for the standard model and $249.99 for the Pro, per reports from SoundGuys and PhoneArena.

Features teased in One UI 8.5 firmware animations and leaks include head gesture controls for calls and media, potentially expanding on Samsung’s existing gesture ecosystem.

Battery improvements are rumored for the Pro variant, with increased capacity to address common complaints about prior models’ runtime. Enhanced active noise cancellation (ANC), improved spatial audio via 360 Audio, and deeper integration with Galaxy AI features — such as real-time translation and adaptive sound — are anticipated, building on the Buds 3 Pro’s AI-driven optimizations.

Advertisement

Certifications confirm global availability soon after announcement, with model numbers SM-R540 for the Galaxy Buds 4 and SM-R640 for the Buds 4 Pro. These filings across multiple regions indicate broad market rollout, likely starting in March 2026 following the Feb. 25 reveal.

The timing comes as Samsung seeks to strengthen its ecosystem ahead of intensifying rivalry in the premium TWS segment. Apple’s AirPods Pro 3 rumors point to similar launch windows, while Sony and Google continue to push ANC and spatial audio advancements. Samsung’s decision to maintain pricing could appeal to cost-conscious consumers amid economic pressures, especially if the Buds 4 deliver meaningful upgrades in comfort, call quality and battery life.

Previous generations faced mixed reception: The Galaxy Buds 3 series drew praise for stem redesigns and sound quality but criticism for fit issues and minor reliability concerns in early units. Leakers suggest Samsung has addressed some of these with the Buds 4’s iterative changes, including better ergonomics and durability.

Samsung has not officially commented on the leaks or confirmed details. The company typically reveals full specifications, including exact battery life, driver configurations, IP ratings and Galaxy-exclusive features, during Unpacked keynotes.

Advertisement

For consumers, the Feb. 25 event represents a major opportunity to upgrade audio gear alongside new smartphones. Pre-orders are expected to open immediately following the announcement, with wide availability in Samsung stores, carriers and retailers shortly thereafter.

As the date approaches, anticipation builds for how the Galaxy Buds 4 series will position itself against competitors. With stable pricing, fresh designs and AI enhancements, Samsung appears ready to maintain momentum in the wireless earbuds market.

Continue Reading

Trending

Copyright © 2025